ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
03 Feb 2023 08:00

Hong Kong Connect Flows Monthly: Health Care Led Inflows in Jan

We analyzed the Hong Kong Connect Scheme for January and highlight flows for China Mobile, BYD, Simcere, ICBC, CNOOC, Meituan, Geely, CCB, Country...

Logo
416 Views
Share
bearishOASIS /Korea
26 Jan 2023 12:08

Oasis Corporation IPO - Thoughts on Valuation

OASIS Corp (370190 KS) is looking to raise up to US$166m in its upcoming Korea IPO. Previously, we looked at the company’s past performance and...

Logo
Ethan Aw
433 Views
Share
bearishMankind Pharma
26 Jan 2023 11:46

Mankind Pharma Pre-IPO - The Negatives - Recent Updates Weren't Great

Mankind Pharma is looking to raise about US$1bn in its upcoming India IPO. In this note, we talk about the not-so-positive aspects of the deal.

Logo
445 Views
Share
bullishZJLD Group
26 Jan 2023 10:31

ZJLD Group Pre-IPO Tearsheet

ZJLD Group (ZJLD HK) is looking to raise up to US$400m in its Hong Kong IPO. The deal will be run by Goldman Sachs and China Securities.

Logo
583 Views
Share
26 Jan 2023 08:05

Hong Kong Connect Flows (Jan 20th): China Mobile, Tencent, Meituan, CCB, HKEX

We analyzed southbound Hong Kong connect flows in the past week and highlight flows for China Mobile, Tencent, Meituan, China Construction Bank,...

Logo
284 Views
Share
x